Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KI guidance

This article was originally published in The Tan Sheet

Executive Summary

Color and appearance of potassium iodide (KI) tablets in federal agency, state and local emergency stockpiles should be monitored to assess stability, FDA states in a 1guidance on KI shelf life extension slated for publication in the Federal Register March 8. Although numerous studies have proven the supplements do not degrade significantly over time, FDA suggests "samples of three batches of KI tablets from each manufacturer be selected and stored under controlled conditions of temperature and humidity and that the samples be tested periodically for compliance with [U.S. Pharmacopeia] assay and dissolution specifications." The guidance, which updates a similar release from April 2002, has been revised to recommend confirmatory testing after two years...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel